Chai Discovery
AI-driven biotech for drug discovery
CORE INFO
Chai Discovery is a biotechnology company that uses artificial intelligence to design and develop new medicines, focusing on creating antibodies to target diseases that traditional methods struggle with. Their AI models, like Chai-2, are tailored for precision in drug discovery, appealing to pharmaceutical companies looking to enhance their drug development processes.
- Chai Discovery recently raised $130 million in a Series B funding round, co-led by Oak HC/FT and General Catalyst, valuing the company at $1.3 billion.techcrunch.com
- The company has partnered with pharmaceutical giant Eli Lilly to utilize their AI models in accelerating drug discovery before clinical trials.techcrunch.com
- Chai Discovery was recognized in Forbes' AI 50 list in 2026, highlighting its impact in the AI-driven drug discovery space.forbes.com
WHY WE WOULD WORK AT CHAI DISCOVERY
Revolutionary Drug Discovery
Join a team pioneering AI-driven solutions like Chai-2, transforming how new therapies are discovered and developed.
Innovative Team Culture
Collaborate with a diverse group of 51 talented individuals, fostering a culture of innovation and creativity in biotech.
Strong Financial Backing
Benefit from substantial funding of $230 million, including a recent $130 million Series B, ensuring stability and growth.
Impactful Work
Contribute to groundbreaking projects that target challenging diseases, making a real difference in healthcare and patient lives.
Cutting-Edge Technology
Utilize proprietary AI models to design antibodies with high precision, pushing the boundaries of traditional drug discovery methods.
Recognized Excellence
Be part of a company featured in Forbes' AI 50 list, highlighting Chai Discovery's significant achievements and industry impact.
MARKET AND TRACTION
TOTAL ADDRESSABLE MARKET
NOTABLE CUSTOMERS
KEY METRICS
✦ KEY METRICGROWTH TACTICS
COMPETITIVE ADVANTAGE
PRODUCT AND TECH
Chai-2 Antibody Design
Chai-2 is a proprietary AI model developed by Chai Discovery for de novo antibody design, enabling the generation of antibodies with high precision. This technology targets diseases that are challenging for traditional methods, significantly accelerating the drug discovery process.
AI-Driven Drug Discovery
Chai Discovery utilizes advanced artificial intelligence to enhance the drug discovery process, focusing on the design and development of new medicines. This approach not only streamlines the identification of potential therapies but also aims to revolutionize how new drugs are brought to market.
Partnerships with Pharma
Chai Discovery has established strategic partnerships with major pharmaceutical companies, such as Eli Lilly, to leverage its AI models in drug discovery. These collaborations enhance the efficiency of drug development before clinical trials, showcasing the practical applications of their technology.
Investment and Growth
With a total funding of $230 million, including a recent Series B round that valued the company at $1.3 billion, Chai Discovery is positioned for significant growth. This financial backing supports the expansion of their innovative technologies and research capabilities.
Biotechnology Focus
Chai Discovery operates at the intersection of biotechnology and artificial intelligence, specializing in molecular design and drug discovery. This focus allows the company to tackle complex challenges in healthcare, advancing the development of new therapies.